Literature DB >> 20427056

Effect of beta-blocker use on outcomes after discharge in patients who underwent cardiac surgery.

Anita Y M Chan1, Finlay A McAlister, Colleen M Norris, David Johnstone, Jeffrey A Bakal, David B Ross.   

Abstract

OBJECTIVE: Beta-blockers improve outcomes in patients with heart failure or a history of myocardial infarction, but it remains uncertain whether they are beneficial after the perioperative period in cardiac surgery patients without these conditions. This study was designed to examine whether discharge use of beta-blockers was associated with outcomes after hospitalization in patients who had undergone nontransplant cardiac surgery.
METHODS: We analyzed outcomes in a prospective cohort of 3102 patients discharged alive after cardiac surgery (2547 of whom had undergone coronary artery bypass grafting surgery) between September 2002 and August 2005.
RESULTS: Beta-blockers were prescribed for 2580 (83%) patients at hospital discharge. Over a mean follow-up of 75 months (standard deviation, 20 months), 10% (259/2580) of patients discharged with beta-blockers and 19% (97/522) not prescribed beta-blockers at the time of hospital discharge died (hazard ratio of 0.65 [95% confidence interval, 0.49-0.87] after adjustment for covariates). One-year mortality was also lower in those discharged with beta-blockers: 2.2% (57/2580) in beta-blocker users versus 7.2% (38/522) in nonusers (adjusted odds ratio, 0.54 [95% confidence interval, 0.30-0.97]). The association between beta-blocker use and lower mortality was consistent across all examined subgroups, including patients without prior myocardial infarction or without heart failure (all P < .01).
CONCLUSIONS: Patients discharged with beta-blockers after cardiac surgery exhibit a substantially lower mortality rate during long-term follow-up, even among those without a history of myocardial infarction or heart failure. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427056     DOI: 10.1016/j.jtcvs.2010.03.015

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery.

Authors:  Heng Zhang; Xin Yuan; Haibo Zhang; Sipeng Chen; Yan Zhao; Kun Hua; Chenfei Rao; Wei Wang; Hansong Sun; Shengshou Hu; Zhe Zheng
Journal:  Circulation       Date:  2015-04-23       Impact factor: 29.690

2.  Discharge β-Blocker Use and Race after Coronary Artery Bypass Grafting.

Authors:  Wesley T O'Neal; Jimmy T Efird; Stephen W Davies; Jason B O'Neal; William F Griffin; T Bruce Ferguson; W Randolph Chitwood; Alan P Kypson
Journal:  Front Public Health       Date:  2014-07-29

3.  Do practice gaps exist in evidence-based medication prescription at hospital discharge in patients undergoing coronary artery bypass surgery & coronary angioplasty?

Authors:  Pradeep Pereira; Aditya Kapoor; Archana Sinha; Surendra K Agarwal; Shantanu Pande; Roopali Khanna; Nilesh Srivastava; Sudeep Kumar; Naveen Garg; Satyendra Tewari; Pravin Goel
Journal:  Indian J Med Res       Date:  2017-12       Impact factor: 2.375

4.  Effect of medications after cardiac surgery on long-term outcomes in patients with cirrhosis.

Authors:  An-Hsun Chou; Yu-Sheng Lin; Victor Chien-Chia Wu; Fang-Ting Chen; Chia-Hung Yang; Dong-Yi Chen; Shao-Wei Chen
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

5.  Impact of hypertension on short- and long-term survival of patients who underwent emergency surgery for type A acute aortic dissection.

Authors:  Zhigang Wang; Min Ge; Tao Chen; Cheng Chen; Qiuyan Zong; Lichong Lu; Dongjin Wang
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

6.  Evaluation of β-blocker therapy for long-term outcomes in patients with low ejection fraction after cardiac surgery.

Authors:  Fu-Dong Fan; Hai-Tao Zhang; Tuo Pan; Xin-Long Tang; Dong-Jin Wang
Journal:  BMC Cardiovasc Disord       Date:  2020-08-20       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.